There are 2789 resources available
887P - Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Sung-Bae Kim
Session: ePoster Display
890P - Concordance analysis of PD-L1 CPS in different sample types of head and neck squamous cell cancer
Presenter: Stijn De Keukeleire
Session: ePoster Display
891P - Landscape of NOTCH1 genomic alterations (GA) in head and neck squamous cell carcinoma (HNSCC) and T-ALL
Presenter: Kristian Ikenberg
Session: ePoster Display
892P - The genomic features of Chinese oropharyngeal squamous cell carcinomas and the implications for therapy
Presenter: QUNXING LI
Session: ePoster Display
893P - Clinico-genetic profiling of HRAS mutant head and neck squamous cell carcinoma (HNSCC)
Presenter: Xiuning Le
Session: ePoster Display
894P - Investigation of ARID1A mutation and correlation with immunotherapy biomarker in Chinese head and neck cancer patients
Presenter: Jianming gao
Session: ePoster Display
895P - Disproportional enrichment of FoxP3+CD4+ regulatory T-cells shapes a suppressive tumor microenvironment and provokes anti–PD-1 resistance in head and neck squamous cell carcinoma
Presenter: Chang Gon Kim
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display